Vincent Rajkumar (@vincentrk) 's Twitter Profile
Vincent Rajkumar

@vincentrk

Editor-in-Chief, Blood Cancer Journal; Oncologist; Chair, Board of Directors @IMFmyeloma; Cancer Research; Opinions solely personal views bit.ly/3f4TnJl

ID: 24261916

linkhttps://vincentrk.com calendar_today13-03-2009 21:46:06

52,52K Tweet

79,79K Followers

1,1K Following

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo
Vincent Rajkumar
@vincentrk

2 months ago

Two specific situations where belantamab can have a major impact are 1) Relapsed high tumor burden myeloma that is refractory to other myeloma drugs and where CART or bispeicifics will be too risky. Here even a few doses of belantamab to control myeloma can open up other